Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company targeting neurological diseases, including rare disorders. Its pipeline includes BHV3000-301, BHV3000-302, BHV3000-303, and others. Biohaven Pharmaceutical has a collaboration agreement with Thirty Madison, Inc. d/b/a Cove to facilitate telemedicine evaluations for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, CT.